Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 16.7% on Wednesday . The company traded as high as C$0.11 and last traded at C$0.11. 282,130 shares traded hands during mid-day trading, an increase of 296% from the average session volume of 71,223 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Up 16.7 %
The company’s 50 day simple moving average is C$0.06 and its 200-day simple moving average is C$0.06. The firm has a market cap of C$9.15 million, a P/E ratio of -5.25 and a beta of 0.15.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Further Reading
- Five stocks we like better than Hemostemix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- 3 Small Caps With Big Return Potential
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Investing in Travel Stocks Benefits
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
